OPKO Announces Appointment of Thomas Nusbickel as Senior Vice President of Pharmaceutical Marketing and Market Access

May 10, 2016 8:30am EDT

Download as PDF

MIAMI--(BUSINESS WIRE)--

OPKO Health, Inc. (NYSE: OPK )

today announced the appointment of Thomas Nusbickel as Senior Vice

President of Pharmaceutical Marketing and Market Access to support the

anticipated launch of RAYALDEE ® .

Mr. Nusbickel has over 25 years of pharmaceutical experience with

established large companies, such as Hospira, Amgen and Abbott, with a

career long focus on specialty products and nephrology. He has been

involved in numerous product launches including serving as the global

lead for Amgen’s launch of Sensipar, and has deep connections with

managed care organizations and with key nephrology opinion leaders.

Prior to joining OPKO, Mr. Nusbickel served as Hospira’s Head of U.S.

Market Access, Biologics and as Amgen’s Executive Director, Value Access

and Advocacy.

“OPKO is proud to add Tom to our growing management team responsible for

commercializing RAYALDEE in the U.S. Tom has extensive, successful

experience in launching new products in the U.S. chronic kidney disease

market,” said Phillip Frost, M.D., Chairman and Chief Executive Officer

of OPKO, “and we are confident that he will help drive Rayaldee to great

success.”

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to

establish industry-leading positions in large, rapidly growing markets.

Our diagnostics business includes Bio-Reference Laboratories, the

nation's third-largest clinical laboratory with a core genetic testing

business and a 420-person sales force to drive growth and leverage new

products, including the 4Kscore® prostate cancer test and the Claros®1

in-office immunoassay platform. Our pharmaceutical business features

Rayaldee™, a treatment for secondary hyperparathyroidism in stage 3-4

chronic kidney disease patients with vitamin D insufficiency and VARUBI™

for chemotherapy-induced nausea and vomiting (oral formulation launched

by partner Tesaro, IV formulation in Phase 3). Our biologics business

includes hGH-CTP, a once-weekly human growth hormone injection (in Phase

3 and partnered with Pfizer), a long-acting Factor VIIa drug for

hemophilia (in Phase 2a) and a long acting oxyntomodulin for diabetes

and obesity (in Phase 1). We also have production and distribution

assets worldwide, multiple strategic investments and an active business

development strategy. More information is available at www.opko.com .

View source version on businesswire.com: http://www.businesswire.com/news/home/20160510005271/en/

OPKO Health, Inc.

Tara Mackay, 305-575-4100

Investor Relations

or

Media

Rooney

& Associates

Terry Rooney, 212-223-0689

or

Marion

Janic, 212-223-4017

or

Investors

LHA

Anne

Marie Fields, 212-838-3777

or

Bruce

Voss, 310-691-7100

Source: OPKO Health, Inc.

Released May 10, 2016

email Email Alerts

location_city Company Profile

contact_page Contacts

rss_feed RSS News Feed

account_tree Sitemap